Antibacterial activity of extracellular compounds produced by a Pseudomonas strain against methicillin-resistant Staphylococcus aureus (MRSA) strains
- Viviane F Cardozo†1,
- Admilton G Oliveira†1,
- Erick K Nishio†1,
- Marcia RE Perugini†2,
- Célia GTJ Andrade†3,
- Wanderley D Silveira†4,
- Nelson Durán†5,
- Galdino Andrade†1,
- Renata KT Kobayashi†1 and
- Gerson Nakazato†1Email author
© Cardozo et al.; licensee BioMed Central Ltd. 2013
Received: 1 March 2013
Accepted: 8 June 2013
Published: 17 June 2013
The emergence of multidrug-resistant bacteria is a world health problem. Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) strains, is one of the most important human pathogens associated with hospital and community-acquired infections. The aim of this work was to evaluate the antibacterial activity of a Pseudomonas aeruginosa-derived compound against MRSA strains.
Thirty clinical MRSA strains were isolated, and three standard MRSA strains were evaluated. The extracellular compounds were purified by vacuum liquid chromatography. Evaluation of antibacterial activity was performed by agar diffusion technique, determination of the minimal inhibitory concentration, curve of growth and viability and scanning electron microscopy. Interaction of an extracellular compound with silver nanoparticle was studied to evaluate antibacterial effect.
The F3 (ethyl acetate) and F3d (dichloromethane- ethyl acetate) fractions demonstrated antibacterial activity against the MRSA strains. Phenazine-1-carboxamide was identified and purified from the F3d fraction and demonstrated slight antibacterial activity against MRSA, and synergic effect when combined with silver nanoparticles produced by Fusarium oxysporum. Organohalogen compound was purified from this fraction showing high antibacterial effect. Using scanning electron microscopy, we show that the F3d fraction caused morphological changes to the cell wall of the MRSA strains.
These results suggest that P. aeruginosa-produced compounds such as phenazines have inhibitory effects against MRSA and may be a good alternative treatment to control infections caused by MRSA.
The emergence of multidrug-resistant bacteria is a world health problem [1, 2]. Staphylococcus aureus is one of the most important human pathogens associated with hospital and community-acquired infections. Over the last few decades, the number and proportion of methicillin-resistant S. aureus (MRSA) infections in different countries has increased due to the rise of epidemics in humans [3–5] and other animals, such as dogs, cats, cattle, pigs and exotic species [6, 7]. In Brazil, according to data obtained from the first five years of the SENTRY Antimicrobial Surveillance Program, MRSA strains were among the most prevalent pathogens and contributed to 56% of the nosocomial and community infections . One of the major global clones is the MRSA Brazilian epidemic clone (BEC), a hospital-acquired MRSA strain. Isolates of this strain are typically resistant to multiple antimicrobials .
The expense incurred to control MRSA may be considerable; however, several economic evaluations have indicated that MRSA control programs are cost-effective in terms of reducing the costs of MRSA infections. In a study comparing two neonatal ICUs, the cost of instituting control measures in a stepwise, delayed approach was US$ 49–69 million (€ 38–52 million), while the cost of introducing effective and immediate measures was US$ 1.3 million (€ 1 million) . Another study calculated that the total cost per case of bacteremia that was caused by an antibiotic-resistant strain, including MRSA (50% of the cases), was US$ 88,445 .
The health risks associated with MRSA infections, including its potential to produce invasive infections, particularly in vulnerable patients, and its resistance to multiple antibiotics, warrant the implementation of monitoring programs to control its dissemination. There is a considerable epidemiological interest in tracking strains to gain a more complete picture of the distribution of strains in the population and the dynamics of clonal spread . For years, vancomycin has been used as the drug of choice to treat MRSA infections and was recommended by clinical guidelines; however, the emergence of the vancomycin-resistant S. aureus (VRSA) and vancomycin-intermediate S. aureus (VISA) has made antibacterial therapy difficult. Therefore, new chemotherapeutic compounds to treat and control infections by these microorganisms have been broadly studied and developed .
Recently, some natural antibacterial agents, such Quercus dilatata, Hylomecon hylomeconoides, Eleutherine Americana, Chelidonium majus Linn. (Papaveraceae) and Tabebuia avellanedae compounds, have been tested against MRSA [14–18].
The ability of antibacterial compounds obtained from other bacteria to inhibit methicillin-sensitive S. aureus (MSSA) and MRSA has also been tested [19–21]. Other bacterial compounds known to have antibacterial activity have not been tested against MRSA. We have tested an extracellular compound derived from Pseudomonas aeruginosa that has previously been shown to have antibacterial effects against Xanthomonas citri pv. Citri, which causes citrus cancer lesions .
The aim of this work was to evaluate the antibacterial activity of a compound from P. aeruginosa against MRSA strains.
Materials and methods
Thirty MRSA strains from bacteria collection of the hospital of Londrina State University, and isolated in 2011, Londrina-PR, Brazil. The MRSA strains were isolated from blood, urine, trachea and secretion cultures. Three standard MRSA strains were also used in this work. The strains MRSA N315 , BEC9393  and rib1  were provided by Dr. Elsa Masae Mamizuka (Universidade de São Paulo, São Paulo-SP, Brazil), Dr. Agnes Marie Sá Figueiredo (Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil), and Dr. Wanderley Dias da Silveira (Universidade Estadual de Campinas, Campinas-SP, Brazil), respectively. All strains were stored at - 80°C in stocks containing glycerol (2.5 M).
Extracellular compounds from Pseudomonas aeruginosa
The extracellular compounds were provided by Dr. Galdino Andrade from the Laboratory of Microbial Ecology (Londrina State University, Londrina-PR, Brazil). The method of production has been patented (Patent, 2008#PI0803350-1; http://www.inpi.gov.br). These antibacterial compounds were obtained from the P. aeruginosa LV strain that was isolated from an old citrus canker lesion on the leaves of orange (Citrus sinensis cv. Valence) plants and collected in Astorga, Brazil . The production and purification of these compounds by vacuum liquid chromatography (VLC) were performed as described by Oliveira and collaborators (2011) . The culture supernatants were treated with dichloromethane 1:1 (v:v). The dichloromethane phase (DP) was fractionated using the mobile phase (v/v): hexane (100:F1); dichloromethane (100; F2); ethyl acetate (100; F3); methanol (100; F4); methanol–water (1:1; F5); and water (100; F6). Fractionation was performed again using the following phase (v/v): hexane (100; F3a); hexane-dichloromethane (1:1; F3b); dichloromethane (100; F3c); dichloromethane- ethyl acetate (1:1; F3d); ethyl acetate (100; F3e); ethyl acetate-methanol (1:1; F3f); methanol (100; F3g); methanol–water (1:1; F3h); and water (100; F3i). In this study, the F3 and F3d fractions were used to evaluate the antibiosis effect. All reagents were purchased from Sigma-Aldrich, USA.
Silver nanoparticles from Fusarium oxysporum
The silver nanoparticles were obtained following the method of Durán and collaborators (2005) . After the growth of F. oxysporum culture, 10 g of the biomass was added in 100 ml of distilled water. After incubation of 72 h at 28°C, the solution components were separated by filtration, and AgNO3 at concentration of 10-3M was added and the system was kept for several hours and then the absorbance at 420 nm that corresponds to the plasmon resonance value was determined. The silver nanoparticles were characterized by Transmission Electron Microscopy (TEM) (Carl Zeiss CEM-902, 80 KeV).
The LLC-MK2 cell line was cultured in a 96-well culture plate at a density of 2.5 × 105 cells/well and incubated for 24 h. When the cells were confluent, the non-adherent cells were removed by washing with sterile 0.01 M phosphate buffered saline (PBS). The medium containing different concentrations of F3d (1 to 2000 μ g/ml) was added to each well containing the cells, and the plates were incubated for 72 h. For the controls, the cells were cultured in the growth medium alone or in the presence of 1% dimethyl sulfoxide (DMSO). Cell viability was determined by the dimethylthiazol diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, USA) method, according to the manufacturer’s recommendation. The concentration of the compounds needed to inhibit the viability of cells by 50% (IC50) was determined by regression analysis. The 50% cytotoxic concentration (CC50/72h) and the selectivity index (SI) were calculated using the equation: SI = CC50/IC50.
Evaluation of the antibiosis effect by the agar diffusion technique
The experiment was carried out with three replicates of two fractions obtained from the dichloromethane phase at two concentrations (100 and 500 μg/ml). The negative control was the dichloromethane phase alone (compound solvent). The antibiotic effect of the fraction on the MRSA strains was evaluated on Mueller Hinton agar plates (Difco, USA). MRSA suspensions of 108 colony-forming units (CFU)/ml were grown to log phase, and the diffusion disks were treated with the antibiotic compounds. The plates were incubated at 35°C for 24 h, and the size of the inhibition halos diameter was evaluated (mm). The experiment was repeated three times, and the antibiosis effect was determined by measuring the size of inhibited halos formed around the wells.
Determination of the minimal inhibitory concentration (MIC)
The minimal inhibitory concentrations (MICs) were determined by micro-dilution assays in 96-well plates, as suggested by the CLSI (2011) . In brief, single colonies of bacterial cultures grown in Mueller-Hinton agar (Sigma-Aldrich, USA) media were diluted in saline solution and adjusted to 0.5 on the MacFarland scale, which corresponds to 1.5 × 108 CFU/ml. Then, the bacterial suspensions were diluted in Mueller-Hinton broth (Difco, USA) and plated in 96-well plates at a density of 5.0 × 105 CFU/well. Finally, different concentrations of the analyzed antibiotics and compounds were added to each well to determine the MIC values. As negative control, DMSO (Sigma-Aldrich, USA) alone was added in equal concentrations as the ones used to solubilize the antibiotic compounds. The plates were incubated at 37°C for 18 h, and then the optical density values at 600 nm were determined using a Bio-Rad Microplate Reader model 3550.
Curve of growth and viability
To quantify the effect of compounds on the bacterial growth, a time-response growth curve was obtained in the presence of these antimicrobials. In brief, a single colony forming unit (CFU) of each MRSA strain was diluted in Mueller-Hinton broth and grown for 18 hours at 37°C with constant stirring at 200 rpm. Then, each culture was adjusted to 0.5 index in MacFarland scale and inoculated at a cell density of 106 CFU/ml in 2 ml of Mueller-Hinton broth. For each strain culture was divided in two new cultures of 1 ml each. One culture received the antimicrobial compound and other received only the solvent (control). The bacterial cultures were then incubated at 37°C with constant stirring (200 rpm). In different times, an aliquot of the broth was collected, serial diluted in saline solution, plated on Mueller-Hinton agar media and grown for 18 h at 37°C in order to determine the total CFU of each culture.
Drug interaction studies
Where MIC(Pc) is the MIC of phenazine used combined with the silver nanoparticle, MIC(Pa) is the MIC of free phenzine used alone, MIC(Sc) is the MIC of the silver nanoparticle used combined with phenazine and MIC(Aa) is the MIC of the silver nanoparticle used alone. FIC indexes were interpreted as follows: FIC ≤ 0.5 = synergic interaction; 0.5 < FIC ≤ 1.0 = additive interaction; 1.0 < FIC ≤ 4.0 = no interaction; FIC > 4.0 = antagonist interaction.
Scanning Electron Microscopy (SEM)
For scanning electron microscopy (SEM), suspensions of the MRSA strains (1010 CFU/ml) with and without the antibacterial compound (at about MIC) were spotted onto polylysine-coated glass slides. Each slide was then fixed by immersion in 1 ml of 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 12 h and then post-fixed in 1% OsO4 for 2 h. The fixed samples were dehydrated in an ethanol gradient (70, 80, 90 and 100˚GL) and then were critical point dried in CO2 (BALTEC CPD 030 Critical Point Dryer). Finally, the slides were taped onto stubs, coated with gold (BALTEC SDC 050 Sputter Coater) and observed under a FEI Quanta 200 SEM. All reagents were purchased from Sigma-Aldrich, USA.
Phenazine-1-carboxamide and organohalogen were identified from the F3d fraction. These compounds were extracted, purified, and evaluated for antibiosis effects. The organohalogen specific structure does not identified yet.
It was not possible to determine the 50% cytotoxic concentration of the F3d fraction on LLC-MK2 cells because even with the highest concentration tested (2000 μ g/ml), 84% of the cells were viable, according to the MTT assay.
Diffusion disc-mediated antibiotic treatments against MRSA strains
The MIC and diameters of the zones of inhibition (mm) generated by the F3 fraction diffusion discs against standard MRSA strains grown on agar
F3 disk (500 μg) zone (mm)
F3 disk (100 μg) zone (mm)
Organohalogen (25 μg) zone (mm)
MIC F3 (μg/ml)
MIC F3d (μg/ml)
MIC phenazine (μg/ml)
16 - 27
08 - 15
Minimal Inhibitory Concentration (MIC)
The MICs of the F3 fraction for MRSA strains (N315, BEC9393 and Rib1) were in the range of 125 μg/ml. The MIC for the more purified F3d fraction was equal to the F3 fraction. The MIC for phenazine-1-carboxamide was 250 μg/ml for the MRSA strain N315 (Table 1). These compounds do not have breakpoints because they are new antibiotics (Table 1). The MRSA strain N315 was further selected for curve of growth and viability tests and scanning electron microscopy.
Curve of growth and viability
Drug interaction studies
Phenazine-1-carboxamide was combined with silver nanoparticle for evaluation synergic effect against MRSA N315 strain. The MICs for phenazine and nanoparticle alone were 250 μg/ml and 125 μM respectively. The MICs for these compounds combined were 7.81 μg/ml and 31.25 μM, showing the FIC at 0.281 (synergic interaction).
Scanning Electron Microscopy (SEM)
The continuous selection of bacteria that are resistant against a wide range of antibiotics necessitates the discovery of novel unconventional sources of antibiotics, mainly in hospitals. Methicillin-resistant S. aureus (MRSA), Escherichia coli O157:H7, Mycobacterium tuberculosis and P. aeruginosa have been considered some of the most virulent microorganisms for the human population.
Notably, MRSA and VISA strains have a thickened cell wall that is believed to deplete the vancomycin available to kill the bacterium; this mechanism of resistance would significantly impact the near future prospects of the current anti-MRSA therapies. The methanol crude extract of Brassica oleracea L. (red cabbage) was investigated for possible antimicrobial activity. The anti-MRSA activity of the red cabbage extract and its underlying mechanism of action appear to be novel and different from other known antibiotics. Accordingly, the discovery of natural, effective, and cheap drugs against this resistant bacterium may be a breakthrough solution for this worldwide problem .
The pentacyclic triterpenoids α-amyrin, betulinic acid and betulinaldehyde and other related triterpenes, such as imberbic acid, oleanolic acid (oleanic acid), ursolic acid, ulsolic acid, rotundic acid and zeylasteral, have been reported to possess antimicrobial activity . Preliminary studies have shown that the pentacyclic triterpenoids have weak antibacterial activity against the reference strains of methicillin-resistant (ATCC 43300) . All three triterpenoids exhibited a bacteriostatic effect against the reference strains of S. aureus at the concentrations tested. Synergism against the two reference strains was reproducibly observed between the three compounds and cell wall inhibitors of the β-lactam and glycopeptide classes. The best synergistic combination was betulinic acid and methicillin .
The bactericidal effect of the ethanolic extracts of the stem bark of cinnamon (Cinnamomum zeylanicum; CIN), the flower bud and stalk of clove (Syzygium aromaticum, CLV) and the seed of cumin (Cuminum cyminum, CMN) were tested on MRSA. In decreasing order, the antibacterial activities for the spices were C. zeylanicum > S. aromaticum > C. cyminum. All three spices were excellent bactericidal agents and are potential anti-MRSA agents .
Thiomarinols, produced by marine bacteria belonging to the genus Pseudoalteromonas, are hybrids of two independently active species: the pseudomonic acid mixture, mupirocin, which is used clinically against MRSA, and the pyrrothine core of holomycin. Thiomarinols are a novel family of natural compounds with potent antimicrobial activity. Understanding how complex antibiotics are synthesized by their producer bacteria to create new families of bioactive compounds .
Recently, the violacein produced by Chromobacterium violaceum has an inhibitory effect against S. aureus isolated from bovine mastitis and displays synergism with penicillin .
The F3 compound studied in this work is effective against Xanthomonas citri pv. Citri, which causes citrus canker lesions . The F3 fraction was initially tested against other bacteria such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumoniae, E. coli, P. aeruginosa and Salmonella enterica serovar Typhimurium and Enteritidis. The initial results demonstrated that the compound was effective against S. aureus, S. epidermidis, Enterococcus faecium and K. pneumoniae (data not shown). Among these bacteria, Staphylococcus spp. had the largest inhibition zones in the diffusion disc test.
Because many hospital infections involve MRSA, we evaluated the effect of the F3 fraction standard and clinical strains on MRSA.
The zones of inhibition in the diffusion disc test and the MICs for the F3 fraction were similar among the standard and clinical MRSA and MSSA strains. The MICs for MRSA were higher than for X. citri; however, these results are very significant and important for therapies used to treat diseases caused by these strains. For the experiments discussed, the F3d fraction was purified from the F3 fraction.
When we evaluated the F3d effect, we found that within a few hours (2 to 5 h), the number of CFUs decreased significantly, indicating that this compound acts rapidly on these strains. In our in vitro tests, the F3d fraction had a bactericidal effect at 200 μg/ml.
By electron microscopy, we observed cellular morphological alterations within a few hours of incubation with lower concentrations of the F3d fraction. The alterations were similar to the effects on X. citri. In addition to reducing of the number of CFUs, we observed deformation and sinking of the bacterial cell wall (Figure 3C and 3D).
The results of the cytotoxicity assay demonstrated that the F3d compound does not have cytopathic effects and is not cytotoxic to LLC-MK2 cells, suggesting low toxicity to the host. Thus, this compound could be used in patients, without side-effects.
Some studies have demonstrated that phenazine efficiently inhibits the growth of bacterial and fungi [36, 37]. There are no studies showing that phenazine-1-carboxamide has an antibacterial effect on MRSA. Another study has reported that phenazine has antimicrobial activity on major rice pathogens, such as Rhizoctonia solani and Xanthomonas oryzae pv. Oryzae . Ecological investigations of the action and crucial role of phenazines have focused in suppressing fungal pathogens of plants such as Fusarium oxysporum and Gaeumannomyces graminis.
The combination of phenazine-1-carboxamide and silver nanoparticle produced by F. oxysporum showed synergic effect decreasing up to 32 times the MIC value of phenazine. Studies involving synergism have been very important for antibacterial therapy mainly for multiresistant bacteria. Some natural products have shown anti-staphylococcal activities weaker than others antibiotics, but synergic interactions may use different mechanism of action or pathways to demonstrate their antimicrobial effects, as resulting in the lowered MICs . The combination of current antibiotics with plant-derived antibacterial agents has showed synergic effect against MRSA .
An organohalogen compound also was identified from F3d fraction and showed high inhibitory activity against MRSA strain N315. The specific structure has not been identified, but future studies on this organohalogen will conducted. Like penicillin, morphine, vincristine, aspirin and other natural products, several natural organohalogens have important medicinal value [41, 42]. The 2,4-dibromophenol-6-chloro compound isolated from a marine filamentous bacterium, Pseudoalteromonas luteoviolacea, shows antibacterial activity against MRSA .
There are few effective antimicrobials against multiresistant bacteria including MRSA strains. These antimicrobials are often associated with high costs and serious side effects for the patients. Many different natural antimicrobials have been studied as an alternative to control these infections. Our study suggests that the use of a secondary metabolite from bacteria such as P. aeruginosa could be effective again MRSA strains that cause diseases in humans and other animals. This compound may be a good alternative to treat and control of infections caused by MRSA.
To the National Council of Scientific and Technological Development (CNPq), Araucária Foundation - Paraná State, and Coordination of Improvement of Higher Education Personnel (CAPES), who enabled the execution of this study. The authors thank Dr. Elsa Masae Mamizuka and Dr. Agnes Marie Sá Figueiredo for providing the standard strains.
- Buke C, Armand-Lefevre L, Lolom I, Guerinot W, Deblangy C, Ruimy R, Andremont A, Lucet JC: Epidemiology of multidrug-resistant bacteria in patients with long hospital stays. Infect Control Hosp Epidemiol. 2007, 28: 1255-1260. 10.1086/522678View ArticlePubMedGoogle Scholar
- Strateva T, Ouzounova-Raykova V, Markova B, Todorova A, Marteva-Proevska Y, Mitov I: Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol. 2007, 56: 956-963. 10.1099/jmm.0.46986-0View ArticlePubMedGoogle Scholar
- Stefani S, Varaldo PE: Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect. 2003, 9: 1179-1186. 10.1111/j.1469-0691.2003.00698.xView ArticlePubMedGoogle Scholar
- Rodríguez-Noriega E, Seas C, Guzmán-Blanco M, Mejía C, Alvarez C, Bavestrello L, Zurita J, Labarca J, Luna CM, Salles MJ, Gotuzzo E: Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Int J Infect Dis. 2010, 14: e560-566. 10.1016/j.ijid.2009.08.018View ArticlePubMedGoogle Scholar
- Lee AS, Huttner B, Harbarth S: Control of methicillin-resistant Staphylococcus aureus. Infect Dis Clin North Am. 2011, 25: 155-179. 10.1016/j.idc.2010.11.002View ArticlePubMedGoogle Scholar
- Weese JS: Methicillin-resistant Staphylococcus aureus in animals. ILAR J. 2010, 51: 233-244. 10.1093/ilar.51.3.233View ArticlePubMedGoogle Scholar
- Smith TC, Pearson N: The emergence of Staphylococcus aureus ST398. Vector Borne Zoonotic Dis. 2011, 11: 327-339. 10.1089/vbz.2010.0072View ArticlePubMedGoogle Scholar
- Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC, : SENTRY Antimicrobial Surveillance Program Report: Latin America and Brazilian results for 1997 through 2001. Braz J Infect Dis. 2004, 8: 25-79. 10.1590/S1413-86702004000100004View ArticlePubMedGoogle Scholar
- Oliveira G, Faria J, Levy C, Mamizuka EM: Characterization of the Brazilian endemic clone of methicillin-resistant Staphylococcus aureus (MRSA) from hospitals throughout Brazil. Braz J Infect Dis. 2001, 5: 163-170. 10.1590/S1413-86702001000400001View ArticlePubMedGoogle Scholar
- Karchmer TB, Durbin LJ, Simonton BM, Farr BM: Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2002, 51: 126-132. 10.1053/jhin.2002.1200View ArticlePubMedGoogle Scholar
- Laupland KB, Lee H, Gregson DB, Manns BJ: Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006, 63: 124-132. 10.1016/j.jhin.2005.12.016View ArticlePubMedGoogle Scholar
- Crisóstomo MI, Westh H, Tomasz A, Chung M, Oliveira DC, de Lencastre H: The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci USA. 2001, 98: 9865-9870. 10.1073/pnas.161272898View ArticlePubMedPubMed CentralGoogle Scholar
- O’Neill AJ: New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2008, 17: 297-302. 10.1517/135437184.108.40.2067View ArticlePubMedGoogle Scholar
- Jamil M, Ul Haq I, Mirza B, Qayyum M: Isolation of antibacterial compounds from Quercus dilatata L. through bioassay guided fractionation. Ann Clin Microbiol Antimicrob. 2012, 11 (Jamil M, Ul Haq I, Mirza B, Qayyum M): 11-View ArticlePubMedPubMed CentralGoogle Scholar
- Choi JG, Kang OH, Chae HS, Obiang-Obounou B, Lee YS, Oh YC, Kim MS, Shin DW, Kim JA, Kim YH, Kwon DY: Antibacterial activity of Hylomecon hylomeconoides against methicillin-resistant Staphylococcus aureus. Appl Biochem Biotechnol. 2010, 160: 2467-2474. 10.1007/s12010-009-8698-5View ArticlePubMedGoogle Scholar
- Ifesan BO, Hamtasin C, Mahabusarakam W, Voravuthikunchai SP: Assessment of antistaphylococcal activity of partially purified fractions and pure compounds from Eleutherine americana. J Food Prot. 2009, 72: 354-359.PubMedGoogle Scholar
- Zuo GY, Meng FY, Hao XY, Zhang YL, Wang GC: Xu GLAntibacterial alkaloids from chelidonium majus linn (papaveraceae) against clinical isolates of methicillin-resistant Staphylococcus aureus. J Pharm Sci. 2008, 11: 90-94. 10.1002/jps.3080110206.Google Scholar
- Pereira EM, Machado TB, Leal ICR, Jesus DM, Damaso CRA, Pinto AV, de Marval MC, Kuster RM, dos Santos KRN: Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob. 2006, 5: 5- 10.1186/1476-0711-5-5View ArticlePubMedPubMed CentralGoogle Scholar
- Hashizume H, Igarashi M, Sawa R, Adachi H, Nishimura Y, Akamatsu Y: A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3. J Antibiot. 2008, 61: 577-582. 10.1038/ja.2008.78View ArticlePubMedGoogle Scholar
- Cazoto LL, Martins D, Ribeiro MG, Durán N, Nakazato G: Antibacterial activity of violacein against Staphylococcus aureus isolated from bovine mastitis. J Antibiot. 2011, 64: 395-397. 10.1038/ja.2011.13View ArticlePubMedGoogle Scholar
- Ding R, Wu XC, Qian CD, Teng Y, Li O, Zhan ZJ, Zhao YH: Isolation and identification of lipopeptide antibiotics from Paenibacillus elgii B69 with inhibitory activity against methicillin-resistant Staphylococcus aureus. J Microbiol. 2011, 49: 942-949. 10.1007/s12275-011-1153-7View ArticlePubMedGoogle Scholar
- Oliveira AG, Murate LS, Spago FR, Lopes LP, Beranger JPO, San Martin JAB, Nogueira MA, Mello JCP, Andrade CGTJ, Andrade G: Evaluation of the antibiotic activity of extracellular compounds produced by the Pseudomonas strain against the Xanthomonas citri pv. Citri 306 strain. Biol Control. 2011, 56: 125-131. 10.1016/j.biocontrol.2010.10.008.View ArticleGoogle Scholar
- Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K: Whole genome sequencing of methicillin-resistant Staphylococcus aureus, the major hospital pathogen. Lancet. 2001, 357: 1225-1240. 10.1016/S0140-6736(00)04403-2View ArticlePubMedGoogle Scholar
- Soares MJ, Teixeira LA, Nunes MR, da Silva Carvalho MC, Ferreira-Carvalho BT, Figueiredo AM: Analysis of different molecular methods for typing methicillin-resistant Staphylococcus aureus isolates belonging to the Brazilian epidemic clone. J Med Microbiol. 2001, 50: 732-742.View ArticlePubMedGoogle Scholar
- Cury GG, Mobilon C, Stehling EG, Lancellotti M, Ramos Mde C, Martinez R, Brocchi M, Silveira WD: Molecular typing of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated in two metropolitan areas of São Paulo State, Southeast Brazil. Braz J Infect Dis. 2009, 13: 165-169.View ArticlePubMedGoogle Scholar
- Rampazo LGL: Evaluation of the effect of biological agents and their products into the incidence of citrus canker lesions. 2004, Londrina, Brasil: Master thesis, Universidade Estadual de,Google Scholar
- Durán N, Marcato PD, Alves OL, de Souza GIH, Esposito E: Mechanistic aspects of biosynthesis of silver nanoparticles by several Fusarium oxysporum strains. J Nanobiotechnol. 2005, 3: 1-7. 10.1186/1477-3155-3-1.View ArticleGoogle Scholar
- CLSI (Clinical and Laboratory Standards Institute), : Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard, M07-A8. 2011, Wayne, PA, USA: CLSI, 8,Google Scholar
- Chin NX, Weitzman I, Della-Lata P: In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 1997, 41: 850-852.PubMedPubMed CentralGoogle Scholar
- Hafidh RR, Abdulamir AS, Vern LS, Abu Bakar F, Abas F, Jahanshiri F, Sekawi Z: Inhibition of growth of highly resistant bacterial and fungal pathogens by a natural product. Open Microbiol J. 2011, 5: 96-106. 10.2174/1874285801105010096View ArticlePubMedPubMed CentralGoogle Scholar
- Chung PY, Navaratnam P, Chung LY: Synergistic antimicrobial activity between pentacyclic triterpenoids and antibiotics against Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2011, 10: 25- 10.1186/1476-0711-10-25View ArticlePubMedPubMed CentralGoogle Scholar
- Mandal S, Manisha D, Saha K, Pal NK: In vitro antibacterial activity of three Indian spices against methicillin-resistant Staphylococcus aureus. Oman Med J. 2011, 26: 319-323. 10.5001/omj.2011.80View ArticlePubMedPubMed CentralGoogle Scholar
- Fukuda D, Haines AS, Song Z, Murphy AC, Hothersall J, Stephens ER, Gurney R, Cox RJ, Crosby J, Willis CL, Simpson TJ, Thomas CM: A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic. PLoS One. 2011, 6: e18031- 10.1371/journal.pone.0018031View ArticlePubMedPubMed CentralGoogle Scholar
- Laursen JB, Nielsen J: Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. Chem Rev. 2004, 104: 1663-1685. 10.1021/cr020473jView ArticlePubMedGoogle Scholar
- Mavrodi DV, Blankenfeldt W, Thomashow LS: Phenazine compounds in fluorescent Pseudomonas spp. biosynthesis and regulation. Ann Rev Phytopathol. 2006, 44: 417-445. 10.1146/annurev.phyto.44.013106.145710.View ArticleGoogle Scholar
- Jayatilake GS, Thornton MP, Leonard AC, Grimwade JE, Baker BJ: Metabolites from an Antarctic sponge-associated bacterium, Pseudomonas aeruginosa. J Nat Prod. 1996, 59: 293-296. 10.1021/np960095bView ArticlePubMedGoogle Scholar
- Choi EJ, Kwon HC, Ham J, Yang HO: 6-Hydroxymethyl-1-phenazine-carboxamide and 1, 6-phenazinedimethanol from a marine bacterium, Brevibacterium sp. KMD 003, associated with marine purple vase sponge antibacterial phenazines from Brevibacterium sp. KMD 003. J Antibiot. 2009, 62: 621-624. 10.1038/ja.2009.92View ArticlePubMedGoogle Scholar
- Shanmugaiah Y, Mathivanan N, Varghese B: Purification, crystal structure and antimicrobial activity of phenazine-1-carboxamida produced by a growth-promoting biocontrol bacterium, Pseudomonas aeruginosa MML2212. J Appl Microbiol. 2010, 108: 703-711. 10.1111/j.1365-2672.2009.04466.xView ArticlePubMedGoogle Scholar
- Chin-A-Woeng TFD, Bloemberg GV, Lugtenberg BJ: Phenazine and their role in biocontrol by Pseudomonas bacteria. New Phytol. 2003, 157: 520-523.Google Scholar
- Konaté K, Mavoungou JF, Lepengué AN, Aworet-Samseny RRR, Hilou A, Souza A, Dicko MH, M’Batchi B: Antibacterial activity against β- lactamase producing Methicillin and Ampicillin-resistants Staphylococcus aureus: fractional Inhibitory Concentration Index (FICI) determination. Ann Clin Microbiol Antimicrob. 2012, 11: 18- 10.1186/1476-0711-11-18View ArticlePubMedPubMed CentralGoogle Scholar
- Gribble GW: Commercial potential of naturally occurring halo-organics. Spec ChemMag. 2003, 23: 22-24.Google Scholar
- Laus G: Biological activities of natural halogen compounds, of Studies in Natural Products Chemistry, Atta-ur-Rahman. Elsevier Science. 2001, 757-809.Google Scholar
- Jiang Z, Boyd KG, Mearns-Spragg A, Adams DR, Wright PC, Burgess JG: Two diketopiperazines and one halogenated phenol from cultures of the marine bacterium, Pseudoalteromonas luteoviolacea. Nat Prod Let. 2000, 14: 435-440. 10.1080/10575630008043781.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.